One year after reporting a split result on Merck’s Welireg in a key phase 3 trial, the song remains the same for the kidney cancer drug as it continues to show benefits in progression-free survival (PFS) but no significant improvement in overall survival (OS) when compared to Novartis’ chemotherapy Afinitor.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,